Noninvasive assessment of the progression of axon damage is important for evaluating disease progression and developing neuroprotective interventions in multiple sclerosis patients. We examined the cellular responses correlated with diffusion tensor imagingY derived axial (L k ) and radial (L ± ) diffusivity values throughout acute (4 weeks) and chronic (12 weeks) stages of demyelination and after 6 weeks of recovery using the cuprizone demyelination of the corpus callosum model in C57BL/6 and Thy1-YFP-16 mice. The rostrocaudal progression of pathological alterations in the corpus callosum enabled spatially and temporally defined correlations of pathological features with diffusion tensor imaging measurements. During acute demyelination, microglial/macrophage activation was most extensive and axons exhibited swellings, neurofilament dephosphorylation, and reduced diameters. Axial diffusivity values decreased in the acute phase but did not correlate with axonal atrophy during chronic demyelination. In contrast, radial diffusivity increased with the progression of demyelination but did not correlate with myelin loss or astrogliosis. Unlike other animal models with progressive neurodegeneration and axon loss, the acute axon damage did not progress to discontinuity or loss of axons even after a period of chronic demyelination. Correlations of reversible axon pathology, demyelination, microglia/macrophage activation, and astrogliosis with regional axial and radial diffusivity measurements will facilitate the clinical application of diffusion tensor imaging in multiple sclerosis patients.
INTRODUCTION
The pathological features of the most common human demyelinating disease, multiple sclerosis (MS), include demyelination, axonal damage, and inflammation in the acute stages and glial scar formation in chronic stages. Multiple sclerosis patients have variable disease courses; relapsing-remitting disease generally correlates with inflammation, whereas progressive disease more closely parallels axonal degeneration (1, 2) . The complexity and variability of MS have fueled interest in the improvement of noninvasive imaging techniques for the evaluation of patient disease courses and therapeutic responses. Demyelinated lesion areas are typically identified by T2-weighted magnetic resonance imaging (MRI), with active inflammation and blood-brain barrier leakage detected as gadolinium enhancement. Acute axonal damage has been observed in recent MS lesions by immunohistochemistry (IHC) for Aamyloid precursor protein and neurofilament dephosphorylation (3, 4) . Acute axonal damage in neurodegenerative diseases can occur before clinical disease manifestations and may be reversible (5) . However, MRI parameters of demyelination and inflammation have not matched well with evidence of axonal or neurodegeneration, such as MRI-assessed brain atrophy (6, 7) . Therefore, additional noninvasive techniques are needed for the detection of acute axonal damage. In particular, there may be a window for stratifying therapeutic options to prevent axon degeneration in the first year after MS onset (3, 8) .
Diffusion tensor imaging (DTI) has shown promise for the noninvasive detection of white matter injury (9, 10) . Decreased axial diffusivity (L k ) describes water diffusion parallel to white matter fibers and indicates axonal injury in mouse traumatic brain injury models (11, 12) , retinal ischemia with optic nerve degeneration (13Y15), spinal cord injury (16Y18), experimental autoimmune encephalomyelitis (EAE) (19Y22), and corpus callosum (CC) demyelination after cuprizone treatment (23Y25). Furthermore, L k has been used to detect axonal damage in patients with Alzheimer disease (26) and traumatic brain injury (27) and in postmortem specimens from MS patients (28) . The DTI measurement of radial diffusivity (L ± ) increases with experimental demyelination after cuprizone treatment (23Y25) and secondary demyelination resulting from retinal ischemia (13, 15) . The sensitivity of L ± to detect demyelination may, however, be reduced in the presence of axonal injury (24) .
Although L k and L ± measurements can be correlated with axon damage and demyelination, respectively, the potential impact of astrogliosis and inflammatory responses, including microglia/macrophage activation on these parameters, has not been investigated; different degrees or stages of axonal damage could impact L k . For example, acute disease with axonal swellings and varicosities from disrupted axonal transport might alter axial diffusivity to a different extent than when there is chronic demyelination (which is typically associated with reduced axon diameter or atrophy). Similarly, L ± values have not yet been evaluated for distinguishing active versus chronic demyelination or for detecting regions of remyelination.
Here, we correlated L k and L ± diffusivity measurements with quantitative analysis of relevant pathological features in the cuprizone neurotoxicant model of demyelination of the CC in mice (25, 29) . Cuprizone demyelination involves oligodendrocyte apoptosis and microglial activation in the absence of lymphocytic infiltration, that is, similar to the features reported in types III and IV MS lesions (30) . The DTI measurements of L k and L ± were examined with parallel quantitative analysis of myelination, axon damage, gliosis, and microglia/macrophage activation in rostrocaudal regions of the CC over the acute demyelination, chronic demyelination, and remyelination stages of the model.
MATERIALS AND METHODS

Mice
All experimental procedures using mice were approved by the Washington University Animal Studies Committee and/or the Uniformed Services University of the Health Sciences Institutional Animal Care and Use Committee. Male C57BL/6 and Thy1-YFP-16 mice on the C57BL/6 background (both from The Jackson Laboratory, Bar Harbor, ME) were fed ad libitum a diet of 0.2% (wt/wt) cuprizone (oxalic bis-[cyclohexylidenehydrazide]; Sigma-Aldrich, Milwaukee, WI) mixed into milled chow pellets (Harlan Teklad, Indianapolis, IN) beginning at 8 weeks of age.
Diffusion Tensor Imaging
C57BL/6 mice (n = 5) underwent longitudinal DTI at time points throughout specific stages of the cuprizone disease progression. Specific time points for correlation with histological analysis were selected based on our previous longitudinal DTI analysis of cuprizone-treated C57BL/6 mice with scans every 2 weeks (24) as follows: 8 weeks of age before beginning cuprizone (0 week, pretreatment controls); after 4 weeks of cuprizone (acute demyelination); after 12 weeks of cuprizone (chronic demyelination); and after 12 weeks of cuprizone plus 6 weeks of recovery on normal chow (12 + 6 weeks, recovery). As a nontreated control for aging during the prolonged cuprizone treatment time course, C57BL/6 mice (n = 5) fed with normal chow were imaged at 18 weeks of age.
Thy1-YFP-16 mice (n = 3) underwent serial DTI at 8 weeks of age before beginning cuprizone treatment (0 week), after 4 weeks of cuprizone treatment (4 weeks), and after 10 weeks of cuprizone treatment (10 weeks). A set of age-matched Thy1-YFP-16 mice (n = 3) underwent DTI at corresponding time points as nontreated controls that were fed normal chow. Another cohort of Thy1-YFP-16 mice was used for cross-sectional analysis with DTI followed immediately by perfusion for histological analysis. Thy1-YFP-16 mice in this cohort were examined from time points corresponding to before beginning cuprizone (0 week, n = 5), after cuprizone treatment for 4 weeks (n = 5), or after cuprizone treatment for 10 weeks (n = 5, including 2 mice from the longitudinally imaged cohort of yellow fluorescent protein [YFP] mice). For comparison with the C57BL/6 mice, the Thy1-YFP-16 mice were analyzed for the chronic condition after 10 weeks of cuprizone because the changes observed in the C57BL/6 mice were already confirmed at this time point, as in our previous study (24) .
The mice were anesthetized with a mixture of O 2 and 4.5% isoflurane, immobilized in a custom MR-compatible stereotaxic device, and placed on a pad of circulating warm water. Anesthesia was maintained at 1.0% to 1.5% isoflurane in O 2 , and body temperature was maintained at 37-C throughout the DTI examination. A surface coil (outer diameter, 1.5 cm) was placed above the head and served as the receiver. The mouse was positioned inside of a 9-cm inner-diameter Helmholtz transmit coil. The entire preparation was positioned in the center of a 4.7-Tesla Oxford Instruments magnet equipped with a 15-cm inner-diameter actively shielded Oxford gradient coil (20 G/cm, 200-microsecond rise time). The magnet, gradient coil, and Techron gradient power supply were interfaced with a Varian UNITY-INOVA console controlled by a Sun Microsystems Blade 1500 workstation.
Data were acquired using a spin-echo diffusion-weighted imaging sequence. Acquisition parameters were repetition time, Matlab (MathWorks, Natick, MA), defined as previously reported (24) .
Color-coded relative anisotropy maps were composed by associating each of the color channels with the components of the eigenvectors corresponding to L k . The color reflects the primary axis of diffusion: red, left-right; green, superiorinferior; blue, anterior-posterior. The region of interest (ROI) was manually defined as the CC from the midline to under the peak of the cingulum on the color-coded relative anisotropy maps from 0.5-mm slices within the rostral (Fig. 1A) , middle (Fig. 1B) and caudal (Fig. 1C ) CC corresponding to anatomical positions centered at +0.75, j0.25, and j1.75 mm of bregma, respectively, using the point at which the anterior commissure crossed the midline as a means to register alignments (31) . The ROIs were applied to the corresponding L k and L ± maps for subsequent analysis.
Tissue Preparation, Electron Microscopy, and IHC in C57BL/6 Mice Mice were perfused with 2% paraformaldehyde/3% acrolein for processing of alternate sections for electron microscopy (EM) and IHC from the same brain. Brains were dissected and cut on a vibratome into 40-Km sagittal serial sections. Parasagittal sections were processed for EM by postfixing in 2% OsO 4 in 0.1 mol/L phosphate buffer for 1 hour, followed by dehydration in a graduated series of ethanol. Dehydrated sections were then embedded in epoxy resin, and an ROI for analysis was selected within each CC diffusivity values among C57BL/6 mice. One cohort of 5 mice was followed in a longitudinal series from before the start of treatment (pretreatment; 8 weeks of age) and again at 4 and 12 weeks of cuprizone treatment and after 12 weeks of cuprizone treatment followed by a 6-week recovery period on normal chow (12 weeks cuprizone treatment + 6 weeks recovery). A second control cohort of 5 mice was scanned as a nontreated group at 18 weeks of age (18 weeks no cuprizone treatment). Both axial and radial diffusivity values show a rostrocaudal pattern that is most pronounced in the caudal CC. Relative to pretreatment controls, axial values are significantly decreased after 4 weeks of cuprizone treatment ( region (rostral, middle, and caudal). Thin sections (È70 nm) were poststained for 15 minutes in 2% aqueous uranyl acetate and 5 minutes in Reynolds lead citrate. Samples were examined in a Philips CM100 transmission electron microscope, and images were recorded onto 4 Â 5-cm photographic negatives developed according to the manufacturer's instructions. Negatives were scanned at 1,200 dpi and imported into MetaMorph (Molecular Devices) for quantitative analysis, including axon diameter and myelin thickness. A minimum of 100 axons was measured for each ROI in each mouse. Small-diameter axons (G0.3 Km), which are typically within the unmyelinated population, were excluded from analysis to more specifically follow the changes during demyelination within the myelinated fiber population (32) .
Alternate parasagittal floating 40-mm sections were double-immunostained for myelin oligodendrocyte glycoprotein (MOG) using monoclonal antibody 8-81C5 (mouse monoclonal IgG, donated by Dr Minetta Gardinier, University of Iowa, Iowa City, IA) and total neurofilament (NF200; Chemicon, Billerica, MA) (33) . Adjacent sections were doubleimmunostained for total (NF200; rabbit pan-neurofilament antibody) and nonphosphorylated neurofilaments (SMI-32 mouse monoclonal IgG; Covance, Princeton, NJ) to evaluate axonal integrity (4, 34) . The MOG and SMI-32 immunolabeling were detected with Cy3-conjugated donkey antiYmouse IgG F(ab ¶) 2 , and NF200 was detected using donkey antiY rabbit IgG F(ab ¶) 2 conjugated with fluorescein isothiocyanate (Jackson ImmunoResearch, West Grove, PA).
Immunofluorescence images were acquired on an Olympus IX-70 microscope for low-magnification (4Â) analysis using a Spot 2 CCD digital camera (Diagnostic Instruments). High-magnification (63Â objective) images were captured using a Zeiss PASCAL 5 Laser Scanning confocal microscope. Morphometric studies of immunofluorescence were performed using MetaMorph software (Molecular Devices). The pathology of cuprizone toxicity differs along the rostrocaudal extent of the CC (25), therefore, regions of the CC were examined separately for quantitative analysis corresponding to bregma as approximately +0.25 to +0.75 mm (rostral), j0.5 to j1.0 mm (middle), and j1.5 to j2.0 mm (caudal) (31) . NF200-positive and SMI-32Ypositive cross-sectional profiles were counted on high-magnification confocal images that were imported into Adobe Photoshop 7. Axonal damage was estimated as the percentage of SMI-32Ypositive profiles among all neurofilament-positive profiles counted (summation of profiles detected with NF200, SMI-32, or labeled with both antibodies). The total density of axons was approximated by dividing the number of all neurofilament-positive profiles by the area of each ROI.
Tissue Preparation and IHC in Thy1-YFP-16 Mice
At the conclusion of DTI examinations, Thy1-YFP-16 mice were perfused with 4% paraformaldehyde. Coronal brain sections (15 mm) were mounted onto slides and immunostained for NG2 (rabbit polyclonal antibody; Chemicon), carbonic anhydrase II (rabbit polyclonal; Abcam, Cambridge, MA), glial fibrillary acidic protein ([GFAP] mouse monoclonal IgG; Sigma Chemical Co, St Louis, MO), or CD11b (rat monoclonal IgG; Abcam). Immunoreactivity (IR) was detected using goat anti-mouse, rat, or rabbit IgG conjugated with Cy3 (Jackson ImmunoResearch) and coverslipped using the Vectashield mounting medium with 4 ¶,6-diamidino-2-phenylindole (DAPI) to visualize DNA (Vector Laboratories, Burlingame, CA). Immunofluorescence was examined with a Nikon Eclipse 80i fluorescence microscope, and images were acquired with a CCD digital camera using MetaMorph software (Molecular Devices).
To quantify axonal damage, infiltration of microglia/ macrophages, and astrogliosis in Thy1-YFP-16 mice, 2 digital pictures were taken in the midline of the CC from sections for each mouse. Each image (1,392 Â 1,040 pixels) was divided into 30 square subsections, and every subsection that contained the CC was randomized and then scored independently. Custom ImageJ macros were used to blind 2 raters to the group, animal, and section from which each subsection score was derived. A single score for each section was computed by averaging the scored subsections. Axonal injury was scored by modification of a published scale (35) , where 0 = no injured axons, 1 = beaded axons, and 2 = beaded axons and loss of YFP fluorescence. The extent of microglia/macrophage infiltration and astrogliosis was scored in a similar fashion using the following scale: 0 = little to no CD11b or GFAP IR, 1 = mild IR, 2 = moderate IR, 3 = severe IR (36) . For each condition, 3 sections each were scored from 5 mice.
Statistical Analysis
Average DTI values, DAPI staining, YFP axonal damage, and immunostaining for microglia/macrophages and astrogliosis were compared across cuprizone time points of 0, 4, and 10 weeks using rank-based nonparametric tests. Average DTI values were also compared between cuprizone-treated and age-matched nontreated controls at 4 and 10 weeks in Thy1-YFP-16 mice. A Kruskal-Wallis test was used to determine whether any differences exist among the experimental groups. Because the global test indicated that differences did exist, this was followed by pairwise comparisons between experimental groups to identify the times at which differences were observed. A significance level of 0.05 was used for the overall test. Values are expressed as the mean T SEM. The DTI cohorts included 3 Thy1-YFP-16 mice or 5 C57BL/6 mice per condition examined; IHC analysis of Thy1-YFP-16 mice included 5 mice per condition or time point examined.
Quantification of neurofilament profiles detected by immunostaining and axons or myelinated fibers examined by EM was assessed using 1-way analysis of variance with a Newman-Keuls post hoc test. Double-immunofluorescence quantification of the proportion of SMI-32 profiles among those detected with NF200 was assessed using W 2 analysis. Values are expressed as the mean T SEM. The EM and IHC studies of C57BL/6 mice included 3 to 5 mice per condition or time point examined.
cuprizone treatment stages (Fig. 1) . Axial diffusivity values were significantly decreased overall and within each of the 3 regions after 4 weeks of treatment. The L k decrease relative to the pretreatment imaging was more pronounced in the caudal than the rostral CC (34.6% vs 21.5%) (Fig. 1D) . Radial diffusivity values were unchanged after 4 weeks of treatment and were increased overall and within each of the 3 regions after 12 weeks. Relative to pretreatment values, imaging of rostrocaudal slices throughout the CC demonstrated a gradient of increased L ± after 12 weeks that was more pronounced in the caudal than in the rostral CC (41.3% vs 31.3%) (Fig. 1E) .
Myelination Status Across the CC Rostrocaudal Distribution in C57BL/6 Mice
Demyelination throughout the CC after cuprizone administration was evaluated by immunostaining for MOG (Fig. 2) and by EM (Fig. 3) . After 4 weeks of treatment, there was a dramatic rostrocaudal gradient of demyelination (Figs. 2AYC). During acute treatment, demyelinated areas have extensive infiltration and amplification of cells that distort the normal tissue structure and increase the area of the CC (Figs. 2D, E) . Overall, there was a significant increase of CC area at 4 weeks of cuprizone treatment (50.6%; p G 0.001), whereas the CC area at 12 weeks of cuprizone (with or without a subsequent recovery period) was not significantly different from pretreatment values (Fig. 2F) .
Ultrastructural analysis showed significant differences in the proportions of myelinated fibers in each of the 3 CC regions after 4 weeks of cuprizone (Fig. 3B) , with the greatest extent of demyelination in the caudal region (Fig. 3E) . Demyelination throughout the CC was most extensive after 12 weeks of cuprizone (Figs. 3C, E) . After 12 weeks of cuprizone, partial remyelination occurred during the 6-week recovery period, but the proportion of myelinated axons was still significantly less than pretreatment levels in all regions (Figs. 3C, E) .
Axon diameter values were reduced after 4 weeks of cuprizone, even in the rostral CC where axons are not as frequently demyelinated as in caudal regions (Figs. 2AYC, 3E ). Axonal atrophy persisted at 12 weeks of cuprizone treatment, with a significant return toward normal diameters in the rostral and caudal CC during the 6-week recovery period (Fig. 3F) . During the recovery period, myelin thickness was consistently reduced for a given diameter axon (Table) , an indication of remyelination. The ratio of axon diameter to myelinated fiber diameter, called the g ratio, is not as clear an indicator of remyelination during the recovery period when axon diameters remain less than values in nontreated mice (Table) . The complexity of myelin thickness variation with axon diameter is further illustrated on a fiberpopulation basis in Figure 
Immunohistochemical Evaluation of Axonal Damage and Loss
Accumulation of A-amyloid precursor protein, an indication of impaired axonal transport, significantly increased after 3 and 5 weeks of cuprizone treatment but was greatly reduced after chronic demyelination for 12 weeks (23). To evaluate axonal alterations further, we immunostained for SMI-32 to detect dephosphorylated neurofilaments as an indicator of axonal damage along with the pan-neurofilament marker NF200 to detect the total population of axons (Fig. 4) . At 4 weeks of cuprizone, the proportion of axons immunolabeled with SMI-32 was significantly increased only in the caudal CC (Fig. 4D) . By 12 weeks of cuprizone treatment, the proportion of axons immunolabeled for SMI-32 was increased across all CC regions (Fig. 4D) , in contrast to the L k values (Fig. 1D) . The pattern of SMI-32 differences correlated with the axon diameter measurements (Fig. 3F) .
We estimated the total density of axons based on NF200 pan-neurofilament immunolabeling; there were no significant differences in the densities of total neurofilament profiles throughout cuprizone treatment in any CC region or overall (Fig. 4E) . Furthermore, the CC areas were not different between 
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Percentages of myelinated axons in rostral, middle, and caudal regions of the CC. All regions exhibited significant decreases in percent of myelinated axons after 4 weeks of treatment; this persisted through the recovery period (*p G 0.05, **p G 0.01, or ***p G 0.001 relative to nontreated [0 week] controls). In the rostral CC, there was a significant increase in the percent of myelinated axons during the recovery period (##p G 0.01, relative to 12 weeks of cuprizone treatment). (F) There were significant decreases in axonal diameter versus nontreated (0 week) controls after 4 weeks of cuprizone treatment, which persisted through 12 weeks of cuprizone treatment (**p G 0.01 for rostral CC, *p G 0.05 for middle and caudal CC). After 12 weeks of cuprizone treatment and a 6-week period on normal chow, there was a significant recovery in axon diameter (#p G 0.05 for rostral and caudal CC vs 12 weeks cuprizone treatment), approaching the pretreatment values. Scale bars = (AYD) 1 Km. nontreated (0 week) and 12-week cuprizone mice (Fig. 2F) , also suggesting that the total axon numbers were similar overall.
Cuprizone Administration in Thy1-YFP-16 Mice
To examine axonal structure during the cuprizone course, we used coronal sections of Thy1-YFP-16 mice. These mice have chimeric expression of YFP in neurons (35, 37) that permits fluorescence detection of the YFP distribution in longitudinal profiles of axons; this analysis can reveal structural changes such as varicosities and swellings that occur with impaired axonal transport. Thy1-YFP-16 mice exhibited loss of oligodendrocytes in the CC with 4 weeks of cuprizone (Figure, Supplemental Digital Content 2, http://links.lww.com/NEN/A129). Coronal sections were used to characterize YFP axon distribution in the caudal CC region (Fig. 5) , that is, the area with the most extensive pathology after cuprizone treatment (Figs. 2Y4) . In control mice, YFP fluorescence was uniformly distributed along longitudinal axonal profiles, with little or no examples of swelling (Figs. 5A, D) . After 4 weeks of cuprizone treatment, axons frequently showed regions of swelling and sites of apparent loss of YFP giving a beaded appearance in longitudinal profiles (Figs. 5B, E) . With cuprizone treatment continued through 10 weeks (Figs. 5C, F) , the YFP distribution seemed to have partially recovered with less prominent axonal varicosities. Analysis with a relative scoring system confirmed that YFP varicosities at 4 weeks of cuprizone treatment were significantly greater than in the nontreated group or the 10 weeks cuprizone treatment group (Fig. 5G) . Compared with the 4-week time point, the incidence of varicosities was reduced approximately 65% at 10 weeks, indicating partial recovery of axonal integrity; however, values were still significantly above the levels estimated for nontreated mice (p G 0.0001).
The L k and L ± Measurements in Thy1-YFP-16 Mice
Overall patterns of L ± and L k changes from pretreatment through acute and continuous cuprizone administration stages were similar in both Thy1-YFP-16 ( Fig. 6 ) and C57BL/6 ( Fig. 1) mice. The L k values were decreased after 4 weeks, with recovery at 10 weeks of cuprizone treatment (Fig. 6A) . The L ± values were not altered after 4 weeks but then increased significantly by 10 weeks of cuprizone treatment (Fig. 6B) . These similar findings between C57BL/6 and Thy1-YFP-16 mice indicate consistent patterns of L k and L ± measurements and the pathological analyses in each mouse strain.
Cell Populations Within the CC During Cuprizone Treatment in Thy1-YFP-16 Mice
A strong microglia/macrophage response has been reported during early cuprizone treatment (38) after which only a low level of activation seems to continue during prolonged feeding (39) . To correlate the potential impact of the increased cell density during acute demyelination to DTI values and axonal damage, we examined patterns of microglia/macrophage activation with cuprizone treatment relative to axonal damage indicated by YFP distribution in the Thy1-YFP 16 mice. Using immunolabeling for CD11b to monitor microglia/macrophage responses in Thy1-YFP-16 mice, we found that compared with nontreated mice (Figs. 7A, D, G) , the densities of CD11b + cells was very high at 4 weeks of cuprizone treatment; DAPI labeling of nuclei was included to demonstrate the corresponding increase in cell density at this time point (Figs. 7B, E, H) . By 10 weeks of cuprizone treatment, the overall cell density and CD11b IR were similar to nontreated mice, but nuclear staining revealed a lack of organization that is typical in lesion areas (Figs. 7C, F, I ). Quantitative analysis (Fig. 7J) with a relative scoring system of CD11b IR demonstrated that pretreatment values were increased 403% by 4 weeks of cuprizone but recovered to only a 60.5% increase over pretreatment levels at 10 weeks of treatment. This pattern of CD11b IR was similar to the pattern of change in axon damage in the Thy1-YFP-16 mice and, indeed, areas with YFP fluorescence patterns indicative of axon damage corresponded to areas of strong CD11b IR (Figs. 7KYM) .
Astrogliosis has been reported during early cuprizone treatment in C57BL/6 mice (38). We used GFAP IR to estimate the astrocyte response during cuprizone treatment for 4 and 10 weeks. Semiquantitative analysis with a relative scoring system demonstrated an 80% increase in GFAP IR in the caudal CC at 4 weeks, with a further increase of 123% by 10 weeks of cuprizone treatment, relative to pretreatment (0 week) levels in adult Thy1-YFP-16 mice at 8 weeks of age (Fig. 8) . This pattern of progressive changes across both 4 and 10 weeks of cuprizone treatment is not consistent with the pattern observed for L k and L ± measures across these time points.
DISCUSSION
This study extends and refines the interpretation of DTI parameters relative to pathological features during the progression of demyelinating disease in the cuprizone model. Our analysis indicates that DTI-derived L k values are reduced during the initial stages of demyelination in CC regions that are characterized by nonuniform axonal swellings, beads, or varicosities along axon segments, loss of YFP within axons, increased numbers of SMI-32Ypositive axons without loss of total number of axons, and microglia/macrophage activation.
Axial diffusivity was not reduced during chronic demyelination, in which axonal atrophy was prominent. The L ± values generally increased in chronically demyelinated CC regions, but in areas with extensive axonal swelling and beading and marked inflammatory cell infiltration (e.g. the caudal CC at 4 weeks of cuprizone), L ± did not increase possibly because of decreased intra-axonal water diffusivity after injury and/or the increased restriction arising from the infiltrating cells. These discrete differences in DTI signal relative to the onset and progression of white matter pathology are important for the application of DTI for the noninvasive assessment of the complex pathological features of human demyelinating diseases.
Our evaluation of axon pathology by IHC of Thy1-YFP transgenic reporter mice (40) and quantitative EM indicated that axonal swellings and varicosities in the early demyelination stage did not lead to significant axon loss during the course of chronic demyelination. The axonal swellings could be continuous with nonfragmented regions of axons and seemed to resolve between 4 and 10 weeks of cuprizone treatment. This observation is consistent with studies of Thy1-YFP mice with EAE, in which inflammatory lesions exhibited axonal injury and loss of YFP, whereas resolution of inflammation corresponded with return of YFP in axons (41) . When the demyelination period was longer, continued axonal pathology was detected by IHC for dephosphorylated neurofilaments and by reduced axon diameters measured by EM. However, axon densities were similar to those before cuprizone treatment, and a lack of reduction of CC area between pretreatment and chronic cuprizone treatment conditions also indicates a lack of significant axon loss. In MS, however, white matter atrophy is considered to be an indicator of axon loss (42) . The ability of axons to remain viable after demyelination is supported in a recent example of nonimmune demyelinating disease in cats (43) .
Standard MRI of MS patients can monitor disease progression based on the number and size of lesion areas and the presence of gadolinium-enhancing lesions but cannot detect axonopathy; therefore, imaging frequently does not correlate well with neurological impairment. A combination of measurement of T2-weighted, T1-weighted, and magnetization transfer ratio has been suggested to distinguish axonal swelling and axonal loss in chronic MS (44) . In DTI studies of mice with EAE, relative anisotropy was not sufficient to distinguish axonal pathology, although L k detected corresponding axonal damage (22) . In a study of 4 weeks of cuprizone treatment of mice, reduced L k corresponded with optical density area measurements, in which neurofilament immunostaining was decreased and CD11b IR was increased in the caudal CC (25) . Because cellular infiltration increases the area of the CC at this time point, however, decreased optical density of neurofilament IHC may reflect spread in the area occupied by the axons rather than actual loss of axons. Therefore, the current findings are important for characterization of the directional diffusivity signals in analyses of axonal pathology throughout acute and chronic stages of demyelination. Specifically, L k can distinguish regions of axonal swellings and varicosities, without there being a significant loss of axons, along with microglia/ macrophage activation and accumulation (Figs. 6Y8) . Our present results show, however, that L k does not reflect axonal atrophy (Figs. 1Y4; Table) .
The underlying mechanisms of DTI parameter changes responding to CNS injury have been difficult to resolve. Water diffusion in the CNS is affected by numerous cellular elements, including membranes, organelles, and cytoskeletal components, although lipid membranes seem to be the most prominent barriers to the motion of water molecules (45) . These CNS components respond to injury in a highly complex and tightly interwoven manner. The resulting pathologies can occur with different severities and at different stages of the disease process, all of which contribute to the diffusion measurements in unique ways. We found that increased astrogliosis did not parallel the trend of change in L k (Fig. 8) , suggesting that astrogliosis does not correspond with the observed decrease in L k after 4 weeks of cuprizone treatment, whereas microglia/macrophage infiltration coincided with acute axonal damage (Fig. 7) . Thus, both acute axonal damage and microglia/macrophages may contribute to the observed decrease in L k . A multiparametric analysis of mice with EAE revealed that L k was highly correlated with axonal damage; increased cellularity also affected L k , but to a lesser degree (22) . The DTI and histological techniques also have vastly different spatial resolutions, and technical limitations may prevent direct correlations between these modalities (46) . Continued studies to advance this correlation are important because histological determinants can usually provide more sensitive and direct examination of pathological features, whereas DTI measures have strong advantages for noninvasive and longitudinal structural studies that can be performed in vivo.
Detection of axonal abnormalities in MS patients can be complicated by the presence of an inflammatory response in active lesions and scar formation in chronic inactive lesions. During the first year after the onset of MS, axon damage has been correlated with accumulation of CD8 + cytotoxic T cells and activated microglia/macrophages (3) . As in the present study and in EAE (40), CD11b IR was colocalized in areas of axonal damage detected by dephosphorylated neurofilaments and loss of YFP in axons. Accumulation of A-amyloid precursor protein is most extensive during the initial phase of CC demyelination with 3 to 6 weeks of cuprizone treatment, when microglial accumulation is most prominent (23, 39) , but Lindner et al (39) reported that SMI-32 immunostaining was not present after 4 weeks of cuprizone treatment and only began to appear after 8 weeks. This observation has been interpreted as indicating 2 patterns of axonal injury, that is, acute damage versus the slow degeneration, occurring in the cuprizone model (39) . In the present study, however, dissociation of axonal transport disruption and neurofilament dephosphorylation was not observed as there was SMI-32 IR in axonal swellings after 4 weeks of cuprizone treatment (Fig. 4) . Furthermore, we found reduced axonal diameter by EM (Fig. 3) , which is consistent with neurofilament dephosphorylation (47, 48) . Therefore, SMI-32 IR is present during both the acute axon damage associated with swellings and varicosities and during the chronic axon atrophy exhibiting relatively uniform reduction of axon diameter. Evidence from several laboratories using similar methods for the cuprizone model indicates an ability of axons to recover from damage rather than progressing to discontinuity during either acute or chronic stages of demyelination. After 5 weeks of cuprizone treatment, dystrophic axons seem to continue after removal of cuprizone from the diet for 1 or 2 weeks and comprised approximately 5% of the axon populations sampled (49) . Reduction in axon diameter after the acute demyelination episode seems to be largely reversible upon return to normal chow and remyelination (32) . During the chronic cuprizone time course, loss of a small percentage of axons within the CC may occur and is not inconsistent with the current data. The restoration of YFP distribution along axons after the initial demyelination phase suggests that there is a resolution of the swellings and varicosities that might otherwise be expected to precede axon end bulb formation and transection (Fig. 5) . Because our EM preparations were optimized for comparison of neurofilament IHC and ultrastructural analysis of axon diameter and myelin status in proximate sections from the same brain to better correlate these parameters for interpretation of our DTI, resolution of ultrastructural detail of axonal swellings after acute demyelination was not sufficient to determine whether observed accumulations of distended vacuolar structure and other variable electron-dense elements were transient changes or likely to result in axonal disconnection (49) . Similar to the analysis of acute cuprizone demyelination (32), we found reduced axon diameters throughout 12 weeks of treatment, with a significant increase after a recovery period of 6 weeks (Table; Fig. 3F ). Moreover, after chronic demyelination, the remyelination is delayed and incomplete, yet still serves as a significant indicator of axon viability (Fig. 3) .
The mechanism for reversible axonal damage we observed is not clear. Cuprizone challenge causes copper deficiency, leading to dysfunction of oxidative phosphorylation and oligodendrocyte death, which results in demyelination (29) . The model was initially established in weanling mice with white matter pathology targeting the superior cerebellar peduncles (50, 51) and was subsequently adapted in 8-to 10-week-old mice to generate more extensive demyelination, particularly in the CC, and less toxicity (29, 32, 38, 49, 52, 53) . The initial stage of demyelination results in a large cellular infiltrate consisting mainly of activated microglia/macrophages, which function, in part, beneficially to clear apoptotic oligodendrocytes and myelin debris, facilitating spontaneous remyelination at 6 weeks of treatment (54) . The proinflammatory cytokines secreted by activated microglia/macrophages may mediate axonal damage (55) . Microglia/macrophages may similarly function both pathogenically and protectively in MS (56) . In addition, oligodendrocyte progenitor cells proliferate to increase during acute cuprizone demyelination in both C57BL/6 (33) and Thy1-YFP-16 mice (Figure, Supplemental Digital Content 2, http://links.lww.com/NEN/A129). These progenitors differentiate into oligodendrocytes so that partial remyelination begins even while mice are being fed cuprizone, progressing further during the return to normal chow ( Fig. 3 ) (32) . Ongoing attempts at remyelination during the chronic cuprizone treatment may contribute to the preservation of atrophic axons. This rostrocaudal pattern of cuprizone-induced CC demyelination was originally reported after 4 or 5 weeks of treatment (25, 49) . The current study demonstrates that rostrocaudal differences are evident throughout the course of acute and chronic demyelination, with more extensive changes in the caudal CC (Figs. 2, 3) .
In summary, we demonstrate reversible axonal damage after severe acute swelling and robust infiltration of microglia/ macrophages that may provide insight into mechanisms of early axon damage and the factors that mediate progression to discontinuity versus continued viability. The reversibility of axon damage in this model may relate to a lack of cytotoxic T cells and/or the relatively focal extent of injury (38, 57) . The reversibility of demyelination in this model is also a factor because remyelination occurs in the presence of continued cuprizone treatment and demyelination (32) . The noninvasive evaluation of axonal damage and demyelination afforded by L k and L ± measures in the discrete regions analyzed in the mouse CC should enhance the use of DTI parameters in MS and other conditions. In particular, the present results may translate to the development of a noninvasive means of detecting early, potentially reversible, acute axonal damage, with regional specificity that affords a crucial window for effective therapy of MS patients.
